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Patients included in clinical trials must
reliably meet the respective inclusion cri-
teria. Many clinical trials, especially for
acute disorders [e. g., idiopathic sudden
sensorineural hearing loss (ISSHL)], oc-
cur within a busy clinical practice; there-
fore, the screening of inclusion criteria
should be easy and reliable for the in-
vestigator. In addition, when planning
clinical trials, it is necessary to make ac-
curate recruitment estimates based on
retrospective data.
Primary outcomes in clinical trials on
treatments of ISSHL are mainly based on
average pure-tone thresholds [12, 14, 16,
18, 22]. Owingtothenaturalcourseofthe
disease and the biometrical aspects of the
study design, the inclusion and outcome
parameters are very heterogeneous [2, 6,
14].
The severity of hearing impairment
is quantitatively graded using categories,
e. g., “no,” “slight,” “moderate,” “severe,”
and“profound”assuggestedbytheWorld
Health Organization (WHO) [17, 23],
but the threshold levels deﬁning those
categories vary [17]. The WHO deﬁnes
“severe impairment” as pure-tone thresh-
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olds of the better ear of 61–80 dB HL,
whereas theEuropeanWorkingGroupon
Genetics of Hearing Impairment refers
to thresholds of 70–94 dB HL [10]. The
calculation of the mean hearing thresh-
old is often based on a four-frequency
pure-tone average (4PTA), e. g., of the
frequencies 0.5, 1, 2, and 4 kHz [15, 16];
however, a wide variety of outcome pa-
rameters have beenused in ISSHL studies
[14].
Not all frequencies are aﬀected per se
in ISSHL.When studying the eﬀects of an
intervention, it is meaningful to look at
thoseparametersor frequencies thathave
been aﬀected by the diseases. An average
of all frequencies in a certain predeﬁned
region underestimates the eﬀect of an
intervention. Therefore, several authors
used the three most aﬀected frequencies
as primary or secondary outcome mea-
sures for evaluation of the treatment [1,
8, 12, 19]. In these cases, the three most
aﬀected consecutive frequencies are se-
lected and the hearing loss is calculated
at the screening visit relative to a base-
line value. There are diﬀerent options for
baseline reference thresholds. The best
option for inclusion and/or the outcome
measurement would be an audiogram of
the aﬀected ear not too long before the
incident. However, since such an audio-
gram is often not available, studies have
also used the unaﬀected contralateral ear
for comparison [1, 5, 11, 16, 20, 21] or
age- and sex-related normative hearing
[4, 9].
A Microsoft Excel ﬁle was developed
to provide an easy-to-use tool for classi-
fying patients to be included in clinical
trials. This tool allows for the compar-
ison of audiograms with the ISO 7029
norm[7] andautomatically calculates the
severity of absolute and incident-related
hearing loss. The tool provides an inclu-
sion decision, based on the predeﬁned
audiological criteria.
Methods
A Microsoft Excel 2010 (Version 14.0.
7151.5001; Microsoft, Redmond, Wash.)
spreadsheet was developed. The main
user interface with several tables and
a chart are shown in. Fig. 1. Theuser en-
ters the subject-related parameters into
the blue-shaded ﬁelds. The “patient de-
mographic” table contains the optional
ID, age, and sex of the patients. The
user can modify the preset inclusion cri-
teria for the respective clinical trial in the
“inclusion parameters” table. The “min-
imum severity of hearing loss” is deﬁned
as the minimum hearing level (4PTA;
0.5, 1, 2, 4 kHz) of the acute audio-
gram needed for inclusion into the study.
The “minimum hearing level” diﬀerence
is calculated as the maximum diﬀerence
between the mean hearing thresholds of
three consecutive frequenciesof the acute
audiogram and the respective baseline.




4PTA Four-frequency pure-tone average
ISSHL Idiopathic sudden sensorineural
hearing loss
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Fig. 18 “Inclusion criteria spreadsheet” of the software tool showing the user interface for entering the demographics, the
audiograms, and the inclusion parameters for a typical patient
have to be used, the value has to be set
to zero.
The hearing thresholds of the acute
and the baseline audiograms are entered
in the “audiograms” table. Thresholds
above 115 dB HL are “dummy coded”
with 120 dB HL, as suggested previously
[2, 13]. If enough valid data points have
beenentered, the colorof the “data check”
ﬁeld turns from red to green. The color
of the 4PTA ﬁelds changes to green if the
value is higher than the predeﬁned min-
imum severity of current hearing loss.
To calculate the normal age- and sex-
related audiogram for every frequency,
the median hearing threshold is calcu-
lated as requested by the ISO 7029 norm
(see . Fig. 2: worksheet “ISO 7029” of
the software tool).
Grading of hearing impairment is dis-
played for every acute or baseline au-
diogram, assuming it is the better ear.
The WHO and European Commission
scores are displayed based on the data of
the “grading” worksheet (. Fig. 3). Both
grading scores are based on the 4PTA.
Various other classiﬁcation systems [3,
17] can be applied by changing those
data. As the aﬀected ear may often be
the worse hearing ear, the grading calcu-
lation is for qualitative information only.
The “recommendation on inclusion”
is basedon the inclusionparameters, sep-
arately for every baseline audiogram. If
both the severity of hearing loss and the
hearing lossof threeconsecutive frequen-
cies meet the predeﬁned inclusion crite-
ria, a positive decision is recommended
and the color of the ﬁelds change from
red to green. A chart of the baseline and
acute audiograms is provided below the
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tables to provide a visual impression of
the plausibility of the entered data.
The applicability and the eﬃciency
of the tool was evaluated by classifying
audiograms according to the criteria of
a planned, controlled, three-armed, mul-
ticenter, randomized, triple-blind study
on the eﬃcacy and safety of high-dose
glucocorticosteroid treatment of ISSHL.
Retrospectively, audiograms of 100 pa-
tients with ISSHL were classiﬁed to meet
the respective inclusion criteria and the
timeneeded formanual classiﬁcationwas
compared with automatic classiﬁcation
using the tool.
Results
The data of a 65-year-old female candi-
date are shown in . Fig. 1. Pure-tone au-
diograms were available for the aﬀected
ear before and after the incident (i. e.,
a sudden hearing loss). The severity of
the hearing loss was 53.75 dB HL and,
thus, above the predeﬁned value of 50 dB
HL. Grading of hearing impairment (for
the aﬀected ear) was 2, which is “mod-
erate impairment”.
The comparison with the baseline au-
diogram of the aﬀected ear before the
hearing loss shows only one frequency
(2 kHz) with an incident-related diﬀer-
ence above the inclusion criteria (30 dB).
Thus, three consecutive frequencies with
incident-relatedhearing loss couldnotbe
found. When compared with the audio-
gram of the opposite, non-aﬀected ear,
three consecutive frequencies with hear-
ing change due to the incident ≥30 dB
could be found in the frequency ranges of
0.125–0.5 kHz, 0.25–1 kHz, 0.5–2 kHz,
1–3 kHz, and 2–4 kHz. The maximum
mean diﬀerence in three consecutive fre-
quencies was in the range of 0.5–2 kHz
(46.67 dB). Thus, the predeﬁned audi-
ological inclusion criteria were met. If
(1) noprevious audiogramof the aﬀected
ear is available and if (2) according to
the patient’s medical history hearing was
symmetric before the incident, the pa-
tient would be recommended for inclu-
sion into the clinical trial.
The normal age- and sex-related au-
diogram, according to ISO 7029, was cal-
culated and showed slightly better values
than the audiogram of the opposite ear.
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Abstract
Objective. Selecting subjects for clinical trials
on hearing loss therapies relies on the patient
meeting the audiological inclusion criteria. In
studies on the treatment of idiopathic sudden
sensorineural hearing loss, the patient’s
acute audiogram is usually compared with a
previous audiogram, the audiogram of the
non-aﬀected ear, or a normal audiogram
according to an ISO standard. Generally, many
more patients are screened than actually fulﬁll
the particular inclusion criteria. The inclusion
criteria often require a calculation of pure-
tone averages, selection of the most aﬀected
frequencies, and calculation of hearing loss
diﬀerences.
Materials and methods. A software tool
was developed to simplify and accelerate
this inclusion procedure for investigators
to estimate the possible recruitment rate
during the planning phase of a clinical trial
and during the actual study. This tool is
Microsoft Excel-based and easy to modify
to meet the particular inclusion criteria
of a speciﬁc clinical trial. The tool was
retrospectively evaluated on 100 patients
with acute hearing loss comparing the times
for classifying automatically and manually.
The study sample comprised 100 patients
with idiopathic sudden sensorineural hearing
loss.
Results and conclusion. The age- and
sex-related normative audiogram was
calculated automatically by the tool and
the hearing impairment was graded. The
estimated recruitment rate of our sample
was quickly calculated. Information about
meeting the inclusion criteria was provided
instantaneously. A signiﬁcant reduction of
30% in the time required for classifying (30 s
per patient) was observed.
Keywords
Clinical trial · Inclusion criteria · Sudden
hearing loss · Software tool
Thus, the maximum mean diﬀerence in
three consecutive frequencies was in the
range of 0.5–2 kHz (48.33 dB), which is
above thepredeﬁnedcriteriaof≥30dB. In
this case, if (1) no previous audiogram of
the aﬀected ear was available, and (2) ac-
cording to the patient’s medical history
the hearing was not symmetric before
the incident, and (3) there was no for-
mer incident of acute hearing loss in the
aﬀected ear (e. g., due to previous ISSHL
or ear surgery, both of which are often
excluded in sudden hearing loss trials),
a recommendation for inclusion into the
clinical trial would be made.
The mean time needed for manual
classiﬁcation of 100 audiograms was 87 s
(SD: 30 s). When classifying automati-
cally using the tool, the mean time was
57 s (SD: 14 s). The mean time reduc-
tion was 30% (30 s per patient) and was
signiﬁcant [t(99)=11.5, p < 0.001]. The
decision about inclusion or exclusion did
not diﬀer between the methods.
Discussion
Thesoftware toolpresentedhereprovides
an easy method to rapidly obtain infor-
mation about the inclusion of patients
into a clinical trial and can help the in-
vestigator or others who are involved in
selecting appropriate patients for clinical
trials (e. g., referring doctors) to screen
patients for eligibility. The recommenda-
tion can be printed or stored as a digital
ﬁle to be archived. The most important
parameters can quickly be changed and
the tool is easily adaptable to a variety of
studies. Moremodiﬁcationscanbemade,
e. g., including only a singlemost aﬀected
frequency, using a three-frequency aver-
age (e. g., 3PTA0.5–2) instead of a four-
frequency average (e. g., 4PTA0.5–4), or
using thediﬀerent frequencyranges (e. g.,
4PTA0.5–3 vs. 4PTA0.5–4).
We recently classiﬁed our patients
with ISSHL for inclusion in a planned,
controlled, three-armed, multicenter,
randomized, triple-blind study on the
eﬃcacy and safetyofhigh-dose glucocor-
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Calculaon of ISO 7029 hearing threshold
Calculaon Parameters (from ISO 7029)
2
Age (years) 65
Age - 18 years 47
From  ISO detaluclaC9207
8000 0.0220 0.0150 48.60 33.14 50 35
6000 0.0180 0.0120 39.76 26.51 40 25
4000 0.0160 0.0090 35.34 19.88 35 20
3000 0.0115 0.0075 25.40 16.57 25 15
2000 0.0070 0.0060 15.46 13.25 15 15
1500 0.0055 0.0050 12.15 11.05 10 10
1000 0.0040 0.0040 8.84 8.84 10 10
500 0.0035 0.0035 7.73 7.73 10 10
250 0.0030 0.0030 6.63 6.63 5 5
125 0.0030 0.0030 6.63 6.63 5 5
 from actual age and sex
Female Female Male (Hz) Male Female Male Frequency
Hearing loss rounded (dB)Hearing loss (dB)(dB/year) alpha
Fig. 28 “ISO 7029” spreadsheet of the software tool showing the age- and sex-related calculation
parameters from the ISO 7029 norm
Grading of hearing impairment
Grade Descripon min max min max
0 No impairment / 0252lamroN
1 Slight impairment / Mild impairment 26 40 21 39
2 Moderate impairment 41 60 40 69
3 Severe impairment 61 80 70 94
4 Profound impairment including deafness 81 95
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Fig. 38 “Grading”spreadsheetof thesoftware tool showingtheunderlyingparametersusedforhear-
ing loss classiﬁcation.WHOWorldHealthOrganization, EC European Commission
ticosteroid treatment. We could quickly
measure the estimated recruitment rate
(based only on audiological inclusion
criteria). The time reduction necessary
for classifying audiograms using the tool
was signiﬁcant and relevant. In addition,
the tool can be used in other centers for
a proposed trial. The estimated recruit-
ment rate is expected to be more easily
available or evenmore reliable than if the
number of eligible patients is estimated
on a more subjective basis. Thus, the
ﬁnal planning of the number of centers
in a proposed trial might be improved.
Conclusions and practical
relevance
4 The software tool can simplify the
screening of audiograms to compare
with inclusion criteria of clinical trials.
4 It can be used to estimate the re-
cruitment rate of clinical trials as
well.
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